

Accepted Manuscript

Xanthine oxidase inhibitory activity of natural and hemisynthetic flavonoids from *Gardenia oudiepe* (rubiaceae) *in vitro* and molecular docking studies

M.D. Santi, M. Paulino Zunini, B. Vera, C. Bouzidi, V. Dumontet, A. Abin-Carrquiry, R. Grougnet, M.G. Ortega



PII: S0223-5234(17)30974-1

DOI: [10.1016/j.ejmech.2017.11.071](https://doi.org/10.1016/j.ejmech.2017.11.071)

Reference: EJMECH 9946

To appear in: *European Journal of Medicinal Chemistry*

Received Date: 13 October 2017

Revised Date: 21 November 2017

Accepted Date: 25 November 2017

Please cite this article as: M.D. Santi, M. Paulino Zunini, B. Vera, C. Bouzidi, V. Dumontet, A. Abin-Carrquiry, R. Grougnet, M.G. Ortega, Xanthine oxidase inhibitory activity of natural and hemisynthetic flavonoids from *Gardenia oudiepe* (rubiaceae) *in vitro* and molecular docking studies, *European Journal of Medicinal Chemistry* (2017), doi: 10.1016/j.ejmech.2017.11.071.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Xanthine oxidase inhibitory activity of natural and hemisynthetic flavonoids from**

2 ***Gardenia oudiepe* (Rubiaceae) *in vitro* and molecular docking studies**

3 Santi M.D.^{a,b}, Paulino Zunini M.^c, Vera B. ^c, Bouzidi C.^d, Dumontet V.^e, Abin-

4 Carriquiry A.^f, Grougnet R.^d, Ortega M.G.^{a,b*}

5

6 ^a *Farmacognosia, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias*
7 *Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, Haya de la torre y*
8 *Medina Allende, Edificio Ciencias II, X5000HUA Córdoba, Argentina.*

9 ^b *Instituto Multidisciplinario de Biología Vegetal (IMBIV-CONICET), Ciudad Universitaria.*
10 *X5000HUA Córdoba, Argentina*

11 ^c *Center of Bioinformatics, Faculty of Chemistry - UdelaR, 11800 Montevideo, Uruguay*

12 ^d *Laboratoire de Pharmacognosie, UMR/CNRS 8638, Faculté des Sciences*
13 *Pharmaceutiques et Biologiques, Université Paris Descartes, Sorbonne Paris Cité, 4,*
14 *Avenue de l'Observatoire, 75006 Paris, France.*

15 ^e *Laboratoire des Plantes Médicinales de Nouméa, CNRS-Centre IRD, BP 643 98845*
16 *Nouméa Cedex, Nouvelle-Calédonie.*

17 ^f *Department of Neurochemistry, Instituto de Investigaciones Biológicas Clemente*
18 *Estable, 11600 Montevideo, Uruguay*

19

20 **Corresponding author.*

21 *E-mail address: gortega@fcq.unc.edu.ar*

22

23

24

2 Xanthine oxidase (XO), an enzyme widely distributed among mammalian tissues,
3 is associated with the oxidation of xanthine and hypoxanthine to form uric acid.
4 Reactive oxygen species are also released during this process, leading to
5 oxidative damages and to the pathology called gout. Available treatments mainly
6 based on allopurinol cause serious side effects. Natural products such as
7 flavonoids may represent an alternative. Thus, a series of polymethoxyflavones
8 isolated and hemisynthesized from the bud exudates of *Gardenia oudiepe* has
9 been evaluated for in vitro XO inhibitory activity. Compounds **1**, **2** and **3** were
10 more active than the reference inhibitor, Allopurinol ($IC_{50} = 0.25 \pm 0.004 \mu\text{M}$) with
11 IC_{50} values of $(0.004 \pm 0.001) \mu\text{M}$, $(0.05 \pm 0.01) \mu\text{M}$ and $(0.09 \pm 0.003) \mu\text{M}$,
12 respectively. Structure-activity relationships were established. Additionally, a
13 molecular docking study using MOETM tool was carried out to establish the
14 binding mode of the most active flavones with the enzyme, showing important
15 interactions with its catalytic residues.

16 These promising results, suggest the use of these compounds as potential leads
17 for the design and development of novel XO inhibitors.

18

19 **Keywords:** *Gardenia oudiepe*, flavonoid, xanthine oxidase inhibition, molecular
20 docking.

21

22

23

24

2 Xanthine oxidase (XO) has been reported as a key enzyme associated with the
3 oxidation of purines hypoxanthine and xanthine to form uric acid, releasing
4 reactive oxygen species during this catalytic process [1-3]. Structurally, XO is a
5 homodimer widely distributed in mammalian tissues, with a molecular mass of
6 290 kDa. Each subunit contains one molybdenum molybdopterin (Mo-pt), center
7 in which the oxidation process occurs, one flavinadenine dinucleotide (FAD) and
8 two distinct [2Fe–2S] centers [4-6].

9 This enzyme is responsible for the medical condition known as gout,
10 characterized by hyperuricemia and causing oxidative damage to living tissues
11 [4, 7]. Allopurinol is used for the treatment of this pathology, but it has been
12 reported that prolonged use may cause serious side effects such as hepatitis,
13 nephropathy, hypersensitivity and skin rash [7-9]. Thus, alternative XO inhibitors
14 are needed. Aiming at this, numerous non-purine analogues [10] compounds
15 such as, febuxostat [11], curcumin [12], naphthopyrans [13], aloe-emodin
16 derivatives [14], pyrano[3,2-d]pyrimidine derivatives [15], hydroxychavicol
17 analogs [16], flavonoids [1,4-6,8,17-19], chalcones [20] and flavonoid derivatives
18 [21,22], were reported as XO inhibitors.

19 Previously, the influence of the substitution pattern of hydroxy groups on the
20 inhibitory activity of flavones has been reported [1,5,8]. However, the influence of
21 methoxy substituents has not been described.

22 *Gardenia oudiepe* Vieill. (synonym *G. cerifera* S.Moore) is a tree endemic to New
23 Caledonia. The buds and young leaves of this species are covered with a yellow
24 exudate containing rare polymethoxyflavones (PMF) [23]. This exudate
25 constitutes a renewable raw material, its harvest does not damage the plant and

1 access to metabolites does not require any steps of time and solvent-consuming
2 extraction. A single dissolution followed by paper filtration in order to remove
3 small vegetal inclusions provides a mixture available for purification of target
4 compounds.

5 According to the above presented, this work aimed to evaluate the XO inhibitory
6 activity of PMF isolated and semisynthesized from *Gardenia oudiepe* and to
7 establish the mode of ligand-enzyme interaction by molecular modeling.

8 These data may enable the design of new potent inhibitors of XO.

9 **2. Results and discussion**

10 *2.1. In vitro inhibitory activity on xanthine oxidase*


11 In this study seven flavones (compounds **1-6, 9**; Fig. 1) isolated from *Gardenia*
12 *oudiepe* and two semisynthetic derivatives (compounds **7** and **8**) obtained by
13 methylation of **1** and **4** respectively, were evaluated for XO inhibitory activity.

14 All compounds showed a concentration-dependent inhibition. The IC₅₀ values for
15 **1-9** and the reference inhibitor Allopurinol were estimated using nonlinear fitting
16 of concentration-response data (Table 1). Compounds **1, 2** and **3** were active in
17 the nanomolar range, being sixty-three, five and three times, respectively, more
18 active than Allopurinol (IC₅₀, 0.25±0.004 µM) (Fig. 1).

19
20
21
22
23
24
25
26
27
28
29
30

1 **Table 1.** Structures and XO inhibitory activity of PMF. IPT

2

Substitution pattern	Compound	6	7	3'	4'	5'	IC ₅₀ (μM)
	1	H	OH	H	OH	H	0.004±0.001*
	2	OCH ₃	OH	H	OH	H	0.05±0.01*
	3	H	OH	OCH ₃	OCH ₃	OH	0.09±0.003*
	4	OCH ₃	OH	H	OCH ₃	H	0.22±0.08
	5	OCH ₃	OH	OCH ₃	OCH ₃	OCH ₃	4.54±0.10*
	6	OCH ₃	OH	OCH ₃	OCH ₃	OH	6.95±1.30*
	7	H	OCH ₃	H	OCH ₃	H	9.79±1.40*
	8	OCH ₃	OCH ₃	H	OCH ₃	H	14.90±1.20*
	9	H	OCH ₃	OCH ₃	OCH ₃	OH	21.03±1.20*

3 Positive control: Allopurinol IC₅₀ = (0.25±0.004) μM. Media ± SD of at least 3
 4 determinations. *p<0.001, the values resulted significantly different to allopurinol.

5

6

7 2.2. Structure Activity Relationships


8 Previous reports highlighted some structural requirements as the presence of
 9 hydroxy groups in position 5, 7, and 4' of flavones [1,5,8]. The present work
 10 extends these data to compounds bearing a combination of hydroxy and
 11 methoxy substitutions, which were, to our knowledge, never evaluated for XO
 12 inhibitory activity.

13 All tested PMF share a core including a methoxy group on position 3, a hydroxy
 14 on position 5 and oxygenated aromatic carbons on positions 4' and 7. Thus, the
 15 minimal structure is identified as 3-methoxykaempferol (**1**). Variability is due to
 16 different substitution pattern on positions 6 and 7 of the A ring, and 3', 4', 5' of the
 17 B ring (Table 1).

18 Compound **1** has been identified as the most active PMF within this series,
 19 showing an IC₅₀ of 4 nM. In comparison with kaempferol (IC₅₀ 0.09±0.002 μM),
 20 methoxylation of the hydroxyl group in position 3 resulted in a stronger inhibitory
 21 effect. Additional methoxy group on position 6 (compound **2**) or modification on

1 the B ring (compound **3**) led to a 20 fold decrease of the inhibition. Nevertheless,

2 **2** and **3** still demonstrated IC_{50} in the nanomolar range (Fig. 1).



3

4 **Fig. 1.** Concentration-dependent inhibition of xanthine oxidase activity by
5 compounds **1**, **2**, **3**, kaempferol and positive control allopurinol (N = 3).

6 Generally, the most active compounds possess only a 5,7-dihydroxy A-ring. PMF
7 with a 5,7-dihydroxy-6-methoxy A-ring remain strong XO inhibitors if the B-ring
8 has a low steric hindrance, such as **2** and **4**. With this type of A-ring, further
9 substitution on the B-ring by bulkier groups is detrimental to the activity, as
10 observed for **5** and **6**.

11 The replacement of hydroxy group with a methoxy group in position 7 also
12 resulted in dramatically less active derivatives, exemplified by the IC_{50} of **8** and **9**,
13 approximately 70 and 240 fold higher than those of **4** and **3**, respectively.

14 All this structural characteristics remain to be considered in the atomic level later
15 in the docked XO-flavone complexes.

16 *2.3. Docking studies*

1 Computational docking studies were carried out using MOE™ tool (2014) [24], to
2 understand the binding mode of the complexes formed between XO (PDB ID:
3 3NVY) [25] and the most active flavones **1**, **2** and **3**.

4 XO is a homodimer composed by three chain each, with a tertiary structure of
5 two domains, an alpha beta roll and a mainly alpha orthogonal bundle. The
6 catalytic site is located in the first domain [26]. The residues contacting the ligand
7 are near to a beta turn motifs, placed between the H1 alpha helix and a strand
8 belonging to a beta sheet (Fig. 2). The co-crystallized ligand is in H-bond contact
9 with mainly Arg880, Thr1010 and Glu802 [25] In the docking procedure
10 (described in Methods Section) a sphere of 4.5 Å around the co-crystallized
11 ligand was selected as "Site" for docking, including the amino acid residues
12 above described as essential for catalysis.

13

14

15

16

17


18

19

20

21

22



1 **Fig. 2.** Active site of xanthine oxidase (3NVY) complexed with quercetin.

2 As we can observe in electrostatics 2D molecular surfaces (Fig. 3.a-c), the
3 docking study showed that **1**, **2** and **3** were well located into the active site of XO,
4 with the lowest binding energy of -8.2515, -7.7392 and -7.7166 kcal mol⁻¹,
5 respectively. These results are in concordance with those obtained on *in vitro*
6 assays (Table 1). All compounds were surrounded by several aminoacid residues
7 (Glu802, Thr1010, Arg880, Phe914, Phe1009, Leu873, Val1011 and Leu648),
8 that were described as catalytic residues [25]. Additionally, in Fig. 3 are shown
9 the contacts that the compounds have established with the near residues.

10 For the less active flavones **4-9**, the ranking of the scores after docking was -
11 8.3610, -8.5266, -8.2663, -8.0393, -8.1575, -7.8761, respectively.

12

13 **3.a)**

14

15

16

17


18

19

20

21

22



2

3

4


5

6

7

8

9



10 3.c)

11

12


13

14

15

16

17

18 **Fig. 3. a-c.** 2D Electrostatic Surface Map of the best pose docked of 1, 2 and 3

19 respectively. Surface map in the active site: in blue color are the electropositive

20 surface areas and in red color are the negative electrostatic surfaces.

1 A 2D graphic description of the ligand interactions are shown in Fig. 4. The
2 benzopyranone ring of flavones are sandwiched between Phe914 and Phe1009
3 residues, and for **1** and **2**, a π - π interaction between the A ring and the aromatic
4 ring of the Phe914 residue was observed. This interaction was previously
5 reported as important for the recognition of the ligand by XO [17]. It has been
6 reported that Glu802, Glu1261 and Arg880 residues play key roles in the
7 hydroxylation of substrate xanthine [25,27-29]. A hydrogen binding with Glu802
8 residue for all compounds was observed and a H-bond interaction between OH-7
9 and Glu1261, reinforcing the fact that OH-7 assists the inhibitory activity [29]. The
10 B-ring exhibited a hydrophobic interaction with the Leu648 residue, which led to
11 stabilization of the compound inside the active site [30]. Then, we could
12 conjecture that those natural compounds would have the same binding region as
13 the substrate of XO.

14

15

16

17

18

19

20

21

22

23

1 assertion that there is no obvious relationship between the affinities measured by
2 this kind of formalism as docking and inhibition for flavonoids [5]. Further studies
3 such as Molecular Dynamics or Steering molecule dynamic could be envisaged
4 to complete the evaluation.

5 **3. Conclusions**

6 The xanthine oxidase inhibitory activity of nine natural or semisynthetic flavones
7 was evaluated. The raw material is a renewable part of *Gardenia oudiepe*.
8 Cultivation of this tree is easy. Thus, our work is compatible with some criteria of
9 green chemistry and sustainable development. **1**, **2** and **3** were found to be the
10 most active compounds with IC₅₀ values ranging from 4 to 90 nM, being sixty-
11 three, five and three fold more active respectively, comparing to allopurinol
12 (0.25±0.004µM). **4** showed a similar activity to the reference inhibitor.
13 Additionally, structure-activity relationships of these PMF were first established.
14 The molecular docking of **1-3** showed important Van der Waals and hydrogen
15 binding interactions with catalytic residues of the active site of XO as Leu648,
16 Glu802, Glu1261, respectively, which could explain the potent inhibitory activity
17 observed for those compounds. Additionally, the importance of 7-OH previously
18 reported was confirmed, as well as the benzopyrane and the B-ring hydrophobic
19 interactions with lipophilic residues that strongly contribute to the stabilization of
20 the compounds in the active site.

21 These data suggest that active PMF inhibitors of XO may be regarded as
22 candidates for the treatment of disorders where this enzyme is involved, as well
23 as lead for further designing of new compounds with increased XO inhibitory
24 potential.

25 **4. Materials and Methods**

2 Bud exudates of *G. oudiepe* were collected in October 2008 in Forêt Plate, North
3 Province of New Caledonia. A voucher specimen (POU-0290) was deposited at
4 the Herbarium of the Botanical and Tropical Ecology Department of the IRD
5 Center, Noumea, New Caledonia.

6 4.2. General procedure for the isolation of flavones 1-6 and 9

7 200.0 g of flowering buds and leaf bases of *G. oudiepe* covered with exudate
8 was dissolved in 1L of dichloromethane. The solution was filtered using a
9 Buchner funnel. After evaporation to dryness under reduced pressure, 52.0 g of
10 exudate free from buds and leaf pieces were recovered. Repeated
11 chromatographic separations on silica gel column using as eluent gradients of
12 increasing polarity cyclohexane/dichloromethane and dichloromethane/methanol
13 provided compounds 1-6 and 9. Flavones 1-2 and 4-6 were identified by
14 comparison with recently published ^1H and ^{13}C NMR data [23, Supporting
15 Information]. Compound 3: 3,3',4'-trimethoxy-5,5',7-trihydroxyflavone; ^1H NMR
16 (CDCl_3 , 400 MHz): δ 12.63 (bs, 1H, OH-5), 7.27 (d, 1H, $J=2$ Hz, H-6'), 7.22 (d,
17 1H, $J=2$ Hz, H-2'), 6.48 (d, 1H, $J=2$ Hz, H-8), 6.24 (d, 1H, $J=2$ Hz, H-6), 3.89 (s,
18 3H, OCH_3 -3'), 3.85 (s, 3H, OCH_3 -3), 3.80 (s, 3H, OCH_3 -4'); ^{13}C NMR (CDCl_3 , 100
19 MHz): δ 178.9 (C-4), 165.3 (C-7), 162.2 (C-5), 157.3 (C-9), 155.9 (C-2), 153.9 (C-
20 3'), 151.5 (C-5'), 139.8 (C-4'), 139.4 (C-3), 126.9 (C-1'), 110.7 (C-6'), 105.2 (C-
21 10), 104.7 (C-2), 99.6 (C-6), 94.7 (C-8), 60.9 (OCH_3 -4'), 60.8 (OCH_3 -3), 56.8
22 (OCH_3 -3'). Compound 9: 3,3',4',7-tetramethoxy-5,5'-dihydroxyflavone; ^1H NMR
23 (CDCl_3 , 400 MHz): δ 12.57 (bs, 1H, OH-5), 7.35 (d, 1H, $J=2$ Hz, H-6'), 7.33 (d,
24 1H, $J=2$ Hz, H-2'), 6.44 (d, 1H, $J=2$ Hz, H-8), 6.35 (d, 1H, $J=2$ Hz, H-6), 6.03 (bs,
25 1H, OH-5'), 4.01 (s, 3H, OCH_3 -4'), 3.93 (s, 3H, OCH_3 -3'), 3.88 (s, 3H, OCH_3 -3),

1 3.87 (s, 3H, OCH₃-7); ¹³C NMR (CDCl₃, 100 MHz): δ 178.8 (C-4), 165.6 (C-7),
2 162.0 (C-5), 156.7 (C-9), 155.4 (C-2), 152.1 (C-3'), 149.2 (C-5'), 139.5 (C-3),
3 137.8 (C-4'), 125.9 (C-1'), 108.6 (C-6'), 106.1 (C-10), 105.0 (C-2), 98.0 (C-6),
4 92.2 (C-8), 61.1 (OCH₃-4'), 60.3 (OCH₃-3), 56.1 (OCH₃-3'), 55.8 (OCH₃-7).

5 4.3. General procedure for the semi-synthesis of flavones 7 and 8

6 Methylation of compounds 1 and 4 gave respectively flavones 7 and 8 (yield 69%
7 and 71%). Reactions were performed by stirring at room temperature the
8 substrate (100 mg) with dimethyl sulfate (Me₂SO₄, 4 equiv.) and 1,8-
9 diazabicyclo[5.4.0]undec-7-en (DBU, 2 equiv.) in dried acetone for 1 h. The
10 crudes were precipitated and washed with iced water. The resulting residues
11 were solubilized with ethyl acetate (15 mL) and treated with a solution of 1N HCl
12 (3 mL). The final products were extracted with ethyl acetate (3 to 10 mL); the
13 organic phases were washed with a saturated solution of NaCl and dried over
14 Na₂SO₄. After filtration and solvent evaporation, methylated compounds were
15 purified by chromatography on a silica gel column, using as eluent a mixture of
16 dichloromethane/methanol (95/5, v/v). ¹H and ¹³C NMR chemical shifts of
17 derivatives 7 and 8 were in agreement with literature data [23, Supporting
18 Information].

19 4.4. In vitro xanthine oxidase inhibitory activity

20 The assay was performed as previously described by Schmeda-Hirschmann et
21 al., 1992 [31]. Briefly, the assay medium consisting of 21.4 μL of xanthine
22 oxidase solution from bovine milk (0.04 U/mL, Sigma Chemical Co., St Louis,
23 MO, USA), and 0.75 mL of the control solution [K₂HPO₄/ KH₂PO₄ buffer (0.07 M,
24 pH 7.5)] or the sample solution [prepared with each compound dissolved in
25 DMSO and subsequently diluted to the appropriate concentrations with the above

1 buffer] were mixed and preincubated at 25 °C for 15 min. Then, 0.45 mL of the
2 xanthine solution substrate (150 µM, Sigma Chemical Co., St Louis, MO, USA)
3 was added and preincubated at 25 °C for 30 min. The reaction was then stopped
4 by addition of 1 mL of HCL (1N) and the absorbance was measured at 290 nm
5 on a Cary Win UV-VIS spectrophotometer, Varian, Inc., Agilent Technologies
6 (Santa Clara, USA). Allopurinol (Sigma Chemical Co., St Louis, MO, USA) was
7 used as positive inhibitor control. Each treatment was replicated three times. The
8 percent inhibition of xanthine oxidase activity was calculated as follows: %
9 inhibition = $[(Abs_{control} - Abs_{sample})/Abs_{control}] \times 100$, where $Abs_{control}$ is the
10 absorbance of the control solution and Abs_{sample} is the absorbance of the sample
11 solution.

12 4.5. Calculations and statistics:

13 All assays were independently performed in triplicate, and results were
14 expressed as media ± SD of three separate experiments. The IC₅₀ values were
15 estimated using the *GraphPad Prism 6.0* software on a compatible computer.
16 The results were analyzed by unidirectional analysis of variance (ANOVA)
17 followed by the *Bonferroni's* test for multiple comparisons using *GraphPad Prism*
18 *6.0* software.

19 4.6. Molecular docking studies:

20 The crystal from milk bovine xanthine oxidase (PDB ID: 3NVY), co-crystallized
21 with quercetin at 2.0 Å resolution was obtained from the Protein Data Bank
22 (<http://www.rcsb.org/pdb>) [26]. All water molecules were deleted and the
23 hydrogens atoms and charges were adjusted with the MMFF94x forcefield from
24 MOE™ suite (Chemical Computing Group Inc., <http://www.chemcomp.com>)
25 [32,33]. The 3D structures were built and minimized in MOE, using the same
26 forcefield above mentioned. A conformational search with LowmodeMD was

1 carried out to generate different conformers for the docking. LowmodeMD is a
2 conformations search method that uses a short ~1 ps run of Molecular Dynamics
3 (MD) at constant temperature followed by an all-atom energy minimization of all
4 compounds to generate conformations [34]. The docking was performed
5 considering all residues within a 4.5 Å sphere centered on quercetin atoms. As a
6 placement function was selected Alpha Triangle and the scores were calculated
7 with the Affinity ΔG function, which measures the enthalpic contribution to the
8 free energy of binding (MOE™ Chemical Computing Group, 2009), in
9 concordance with a validation procedure [35,36] to reproduce by docking, the
10 same pose of quercetin in the crystal structure. The graphical representations of
11 the calculated binding poses were performed by Surface Maps, and Ligand
12 Interaction MOE™ tools.

13

14 **Acknowledgments**

15 This work was supported by ANPCyT BID–PICT 1576, CONICET D32/10,
16 SECYT-Universidad Nacional de Córdoba (05/C375), MINCyT Cba PID 2010,
17 and by fellowships of the Network of Macrouniversities of Latin America and the
18 Caribbean, and of the Association of Universities Montevideo Group (AUGM).
19 M.D.S. is postdoctoral fellows of CONICET. M.G.O. is member of the Research
20 Career of CONICET. We are indebted to Diego Carvalho Alvarez for his
21 assistance with molecular modeling. The authors also acknowledge the North
22 Province of New Caledonia for facilitation of field investigations, and Cyril Poulain
23 for assistance in plant collection.

24

25 **References**

- 1 [1] D.E. Van Hoorn, R.J. Nijveldt, P.A. Van Leeuwen, Z. Hofman, L. M'Rabet,
2 D.B. De Bont, K. Van Norren, Accurate prediction of xanthine oxidase
3 inhibition based on the structure of flavonoids, *Eur. J. Pharmacol.* 451 (2002)
4 111-118.
- 5 [2] B.C. Behera, B. Adawadkar, U. Makhija, Capacity of some *Graphidaceous*
6 lichens to scavenge superoxide and inhibition of tyrosinase and xanthine
7 oxidase activities, *Curr. Sci.* 87 (2004) 83–87.
- 8 [3] H.C. Lin, S.H. Tsai, C.S. Chen, Y.C. Chang, C.M. Lee, Z.Y. Lai, C.M. Lin,
9 Structure-activity relationship of coumarin derivatives on xanthine oxidase-
10 inhibiting and free radical-scavenging activities, *Biochem. Pharmacol.* 75
11 (2008) 1416-1425.
- 12 [4] C.M. Lin, C.S. Chen, C.T. Chen, Y.C. Liang, J.K. Lin, Molecular modeling of
13 flavonoids that inhibits xanthine oxidase, *Biochem. Biophys. Res. Commun.*
14 294 (2002) 167–172.
- 15 [5] S. Lin, G. Zhang, Y. Liao, J. Pan, Inhibition of chrysin on xanthine oxidase
16 activity and its inhibition mechanism, *Int. J. Biol. Macromol.* 81 (2015) 274–
17 282.
- 18 [6] C. Zhang, G. Zhang, Y. Liao, D. Gong, Myricetin inhibits the generation of
19 superoxide anion by reduced form of xanthine oxidase, *Food Chem.* 221
20 (2017) 1569–1577.
- 21 [7] I. Ahmad, F. Ijaz, I. Fatima, N. Ahmad, S. Chen, N. Afza, A. Malik, Xanthine
22 oxidase/tyrosinase inhibiting, antioxidant, and antifungal oxindole alkaloids
23 from *Isatis costata*, *Pharm. Biol.* 48 (2010) 716–721.
- 24 [8] Y. Dong, H. Huang, M. Zhao, D. Sun-Waterhouse, L. Lin, C. Xiao,
25 Mechanisms underlying the xanthine oxidase inhibitory effects of dietary
26 flavonoids galangin and pinobanksin, *J. Funct. Foods* 24 (2016) 26-36.
- 27 [9] B.P. Bandgar, L.K. Adsul, H.V. Chavan, S.N. Shringare, B.L. Korbadi, S.S.
28 Jalde, S.V. Lonikar, S.H. Nile, A.L. Shirfule, Synthesis, biological evaluation,
29 and molecular docking of N-{3-[3-(9-methyl-9H-carbazol-3-yl)-acryloyl]-
30 phenyl}-benzamide/amide derivatives as xanthine oxidase and tyrosinase
31 inhibitors, *Bioorg. Med. Chem.* 20 (2012) 5649–5657.






- 1 [10] R. Kumar, Darpan, S. Sharma, R. Singh, Xanthine oxidase inhibitors: a patent
2 survey, *Expert Opin. Ther. Pat.* 21 (2011) 1071–1108.
- 3 [11] K. Okamoto, B.T. Eger, T. Nishino, S. Kondo, E.F. Pai, T. Nishino, An
4 extremely potent inhibitor of xanthine oxidoreductase: Crystal structure of the
5 enzyme-inhibitor complex and mechanism of inhibition, *J. Biol. Chem.* 278
6 (2003) 1848–1855.
- 7 [12] L. Shen, H.F. Ji, Insights into the inhibition of xanthine oxidase by curcumin,
8 *Bioorganic Med. Chem. Lett.* 19 (2009) 5990–5993.
- 9 [13] S. Sharma, K. Sharma, R. Ojha, D. Kumar, G. Singh, K. Nepali, P.M.S. Bedi,
10 Microwave assisted synthesis of naphthopyrans catalysed by silica supported
11 fluoroboric acid as a new class of non purine xanthine oxidase inhibitors,
12 *Bioorganic Med. Chem. Lett.* 24 (2014) 495–500.
- 13 [14] D.-H. Shi, W. Huang, C. Li, Y.-W. Liu, S.-F. Wang, Design, synthesis and
14 molecular modeling of aloe-emodin derivatives as potent xanthine oxidase
15 inhibitors, *Eur. J. Med. Chem.* 75 (2014) 289–296.
- 16 [15] M. Kaur, A. Kaur, S. Mankotia, H. Singh, A. Singh, J.V. Singh, M.K. Gupta, S.
17 Sharma, K. Nepali, P.M.S. Bedi, Synthesis, screening and docking of fused
18 pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor, *Eur. J. Med.*
19 *Chem.* 131 (2017) 14–28.
- 20 [16] H.X. Liu, M.T. He, H.B. Tan, W. Gu, S.X. Yang, Y.H. Wang, L. Li, C.L. Long,
21 Xanthine oxidase inhibitors isolated from *Piper nudibaccatum*, *Phytochem.*
22 *Lett.* 12 (2015) 133–137.
- 23 [17] F. Rasoulzadeh, H.N. Jabary, A. Naseri, M.R. Rashidi, Fluorescence
24 quenching study of quercetin interaction with bovine milk xanthine oxidase,
25 *Spectrochim. Acta - Part A Mol. Biomol. Spectrosc.* 72 (2009) 190–193.
- 26 [18] P. Jayaraj, B. Mathew, B. Parimaladevi, V.A. Ramani, R. Govindarajan,
27 Isolation of a bioactive flavonoid from *Spilanthes calva* D.C. in vitro xanthine
28 oxidase assay and in silico study, *Biomed. Prev. Nutr.* 4 (2014) 481–484.
- 29 [19] J. Yan, G. Zhang, Y. Hu, Y. Ma, Effect of luteolin on xanthine oxidase:
30 Inhibition kinetics and interaction mechanism merging with docking simulation,
31 *Food Chem.* 141 (2013) 2766–2773.

- 1 [20] Z. Xie, X. Luo, Z. Zou, X. Zhang, F. Huang, R. Li, S. Liao, Y. Liu, Synthesis
2 and evaluation of hydroxychalcones as multifunctional non-purine xanthine
3 oxidase inhibitors for the treatment of hyperuricemia, *Bioorg. Med. Chem. Lett.*
4 27 (2017) 3602–3606.
- 5 [21] R. Dhiman, S. Sharma, G. Singh, K. Nepali, P.M. Singh Bedi, Design and
6 synthesis of aza-flavones as a new class of xanthine oxidase inhibitors, *Arch.*
7 *Pharm. (Weinheim)*. 346 (2013) 7–16.
- 8 [22] H. Singh, S. Sharma, R. Ojha, M.K. Gupta, K. Nepali, P.M.S. Bedi, Synthesis
9 and evaluation of naphthoflavones as a new class of non purine xanthine
10 oxidase inhibitors, *Bioorg. Med. Chem. Lett.* 24 (2014) 4192–4197.
- 11 [23] L.H. Mai, G.G. Chabot, P. Grellier, L. Quentin, V. Dumontet, C. Poulain, L.S.
12 Espindola, S. Michel, H.T.B. Vo, B. Deguin, R. Grougnet, Antivascular and
13 anti-parasite activities of natural and hemisynthetic flavonoids from New
14 Caledonian *Gardenia* species (Rubiaceae), *Eur. J. Med. Chem.* 93 (2015) 93–
15 100.
- 16 [24] *Molecular Operating Environment (MOE™)* 2015.10, Chemical Computing
17 Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada,
18 H3A 2R7 (2015).
- 19 [25] H. Cao, J.M. Pauff, R. Hille, X-ray Crystal Structure of a Xanthine Oxidase
20 complex with the flavonoid inhibitor quercetin, *J. Nat. Prod.* 7 (2014) 1693-9.
- 21 [26] H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N.
22 Shindyalov, P.E. Bourne, The protein data bank, *Nucleic Acids Res.* 28 (2000)
23 235-242.
- 24 [27] T. Nishino, K. Okamoto, B.T. Eger, E.F. Pai, T. Nishino, Mammalian xanthine
25 oxidoreductase - mechanism of transition from xanthine dehydrogenase to
26 xanthine oxidase. *FEBS J.* 275 (2008) 3278-3289.
- 27 [28] J.M. Pauff, H. Cao, R. Hille, Substrate orientation and catalysis at the
28 Molybdenum site in xanthine oxidase, *J. Biol. Chem.* 284 (2009) 8760-8767.
- 29 [29] S. Lin, G. Zhang, Y. Liao, J. Pan and D. Gong, Dietary flavonoids as xanthine
30 oxidase Inhibitors: structure-affinity and structure-activity relationships, *J.*
31 *Agric. Food Chem.* 63 (2015) 7784-94.

- 1 [30]R. Ojha, J. Singh, A. Ojha, H. Singh, S. Sharma, K. Nepali, An updated patent
2 review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout
3 (2011-2015). *Expert Opin. Ther. Pat.* 27 (2017) 311-345.
- 4 [31]G. Schmeda-Hirschmann, J.I. Loyola, J. Sierra, R. Retamal, J. Rodriguez
5 Hypotensive effect and enzyme inhibition activity of mapuche medicinal plant
6 extracts, *Phytother. Res.* 6 (1992) 184-188.
- 7 [32]T. A. Halgren, MMFF VI. MMFF94s option for energy minimization studies, *J.*
8 *Comput. Chem.* 20 (1999) 720-729.
- 9 [33]P. Labute, LowModeMD—Implicit low-mode velocity filtering applied to
10 conformational search of macrocycles and protein loops, *J. Chem. Inf. Model.*
11 50 (2010) 792–800.
- 12 [34]M.P Allen, D.J. Tildesley, *Computer simulation of liquids* (1987), 231–232;
13 Oxford University Press, Oxford.
- 14 [35]E. Alvareda, P. Miranda, V. Espinosa, H. Pardo, S. Aguilera, M. Paulino
15 Zunini, Antiinflammatory activity of phenolic compounds extracted from
16 Uruguayan propolis and grape, *J. Biomol. Struct. Dyn.* 33 (2015) 129.
- 17 [36] M. Paulino, E. Alvareda, F. Iribarne, P. Miranda, V. Espinosa, S. Aguilera, H.
18 Pardo, Toward the understanding of the molecular basis for the inhibition of
19 COX-1 and COX-2 by phenolic compounds present in Uruguayan propolis and
20 grape pomace., *J. Biomol. Struct. Dyn.* 34 (2016) 2643-2657.



Gardenia oudiepe's
exudate



Highlights

- Xanthine oxidase inhibitory activity of polymethoxyflavones from *Gardenia oudiepe* was determinate.
- Some compounds were more actives than Allopurinol, with IC_{50} in the nanomolar range.
- SAR and docking studies were determinate for those compounds for the first time.